Yes — results are overdue. Primary completion was 2017-10-13; the FDAAA-801 reporting deadline (2018-10-13) passed 2808 days ago and no results are posted on ClinicalTrials.gov.
| NCT ID | NCT03163173 ↗ |
|---|---|
| Sponsor | Galera Therapeutics, Inc. (INDUSTRY) |
| Public issuer | Galera Therapeutics, Inc. — GRTX (CIK 0001563577) best-effort name match, 95% conf — verify on EDGAR ↗ |
| Phase | PHASE1 |
| Status | COMPLETED |
| Primary completion | 2017-10-13 (ACTUAL) |
| Reporting deadline | 2018-10-13 (completion + 365d) |
| Days overdue | 2808 |
| Results posted | No — check results tab ↗ |
| FDA-regulated | drug: yes, device: no |
| Provenance | Flagged overdue on 2026-06-21 · SHA-256 d6ce339c2091fd51… (hash-chained, tamper-evident) |
Source of record: ClinicalTrials.gov NCT03163173. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.